Table 1.
Baseline characteristics.
| Variable | Intervention group (n = 26) | Control group (n = 38) | Total (n = 64) |
|---|---|---|---|
| Gender, n (%) | n = 24 | n = 36 | n = 60 |
| Female | 5 (20.8) | 15 (41.7) | 20 (33.3) |
| Male | 19 (79.2) | 21 (58.3) | 40 (66.7) |
| Age, Mean ± SD [range] | 73.7 ± 12.6 [43–89] | 75.3 ± 13.9 [30–94] | 74.6 ± 13.3 [30–94] |
| Symptoms on admission, n (%) | n = 20 | n = 30 | n = 50 |
| Amnestic aphasia | 5 (25.0) | 8 (26.7) | 13 (26.0) |
| Paresis (Janda grades) | |||
| No discernible muscle contraction (0) | 0 | 1 (3.3) | 1 (2.0) |
| Noticeable reaction, insufficient for movement (1) | 0 | 0 | 0 |
| Full range of motion, not against gravity (2) | 0 | 1 (3.3) | 1 (2.0) |
| Full range of motion against gravity, without resistance (3) | 1 (5.0) | 4 (13.3) | 5 (10.0) |
| Full range of motion against light/moderate resistance (4) | 9 (45.0) | 13 (43.3) | 22 (44.0) |
| Full range of motion against strong external resistance (5) | 10 (50.0) | 11 (36.7) | 21 (42.0) |
| Alertness | 20 (100.0) | 30 (100.0) | 50 (100.0) |
| Anisocoria | 0 | 2 (6.7) | 2 (4.0) |
| Modified Rankin Scale | |||
| 0 | 5 (25.0) | 9 (30.0) | 14 (28.0) |
| 1 | 9 (45.0) | 12 (40.0) | 21 (42.0) |
| 2 | 5 (25.0) | 4 (13.3) | 9 |
| 3 | 0 | 4 (13.3) | 4 (8.0) |
| 4 | 1 (5.0) | 1 (3.4) | 2 (4.0) |
| 5 | 0 | 0 | 0 |
| 6 | 0 | 0 | 0 |
| BMI, n (%) | n = 6 | n = 11 | n = 17 |
| Underweight (< 18.5) | 0 | 0 | 0 |
| Normal weight (18.5–24.9) | 2 (33.3) | 4 (36.4) | 6 (35.3) |
| Pre-obesity (25–29.9) | 2 (33.3) | 3 (27.3) | 5 (29.4) |
| Obesity (> = 30) | 2 (33.3) | 4 (36.4) | 6 (35.3) |
| Type of pre-existing condition, n (%) | n = 25 | n = 37 | n = 62 |
| Alcoholism | 1 (4.0) | 0 | 1 (1.6) |
| Arterial hypertension | 17 (68.0) | 26 (70.3) | 43 (69.4) |
| Autoimmune disease | 0 | 2 (5.5) | 2 (3.2) |
| Diabetes | 10 (40.0) | 9 (24.3) | 19 |
| Coagulopathy | 0 | 0 | 0 (30.6) |
| Liver disease | 1 (4.0) | 0 | 1 (1.6) |
| Kidney disease | 5 (20.0) | 2 (5.5) | 7 (11.3) |
| Tumor disease | 0 | 1 (2.7) | 1 (1.6) |
| Use of anticoagulants/platelet function inhibitors, n (%) | n = 26 | n = 38 | n = 64 |
| Yes | 10 (38.5) | 16 (42.1) | 26 (40.6) |
| ASS (100 mg) | 6 (23.1) | 9 (23.7) | 15 (23.4) |
| Xarelto (20 mg) | 0 | 1 (2.6) | 1 (1.6) |
| Xarelto (15 mg) | 0 | 1 (2.6) | 1 (1.6) |
| Eliquis (10 mg) | 1 (3.8) | 1 (2.6) | 2 (3.1) |
| Eliquis (5 mg) | 1 (3.8) | 1 (2.6) | 2 (3.1) |
| Heparin (40 mg) | 1 (3.8) | 1 (2.6) | 2 (3.1) |
| Lixiana (600 mg) | 1 (3.8) | 0 | 1 (1.6) |
| Marcumar | 0 | 2 (5.3) | 1 (1.6) |
| Genesis of cSDH, n (%) | n = 25 | n = 37 | n = 62 |
| History of acute SDH | 1 (4.0) | 5 (13.5) | 6 (9.7) |
| No history of acute SDH | 15 (60.0) | 23 (62.2) | 38 (61.3) |
| Unclear | 9 (36.0) | 9 (24.3) | 18 (29.0) |
| Embolization performed | n = 26 | ||
| General anesthesia, n (%) | 26 (100.0) | ||
| Number of embolized branches, n (%) | |||
| One branch | 5 (19.2) | ||
| Two branches | 21 (80.8) | ||
| Main trunk embolized, n (%) | 3 (11.5) | ||
| Embolization material, n (%) | |||
| PVA particles | 10 (38.5) | ||
| Liquid embolization material | 16 (61.5) | ||
| Orbital collaterals | 7 (26.9) | ||
| Other “dangerous” collaterals | 1 (3.8) | ||
n/N – number of subjects, % – percentage, mean – arithmetic mean, SD – standard deviation, cSDH – chronic subdural hematoma, PVA – polyvinyl alcohol.